Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796169 | 1.00 | SORD (0.43) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL85415 | 0.84 | CA12 (0.41) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL8663680 | 0.81 | ESR1 (0.42) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL28970337 | 0.81 | CA12 (0.39) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL13680770 | 0.81 | CA12 (0.42) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL20992668 | 0.81 | CA12 (0.39) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL17150578 | 0.81 | CA12 (0.39) | SORDESR1ESR2HIF1ACA12 | |
| SCHEMBL21976909 | 0.78 | FAAH (0.43) | ESR1ESR2HIF1ACA12CA1 | |
| SCHEMBL20229553 | 0.78 | FAAH (0.43) | ESR1ESR2HIF1ACA12CA1 | |
| SCHEMBL24795818 | 0.78 | CA12 (0.44) | ESR1ESR2HIF1ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-06-29 | — | — | US | disclosed |
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-06-29 | — | — | US | disclosed |
| EP-4180090-A1 | BENZISOXAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-115836058-A | Benzisoxazole derivatives | 住友制药株式会社 | 2023-03-21 | — | — | CN | disclosed |
| US-11535599-B2 | Benzisoxazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-27 | — | — | US | disclosed |
| WO-2022009863-A1 | BENZISOXAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2022-01-13 | — | — | WO | disclosed |
| US-5786374-A | FUNGICIDES, MICROBIOCIDES | NOVARTIS CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1996014305-A1 | BENZISOXAZOLE DERIVATIVES AND PESTICIDAL COMPOSITIONS CONTAINING THEM | NOVARTIS AG (CH) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535599-B2 | Benzisoxazole derivative | HDAC3, GABRA5, HDAC2 | SORD 1704/4885ESR1 1775/4885ESR2 2259/4885 |
| US-20230202991-A1 | BENZISOXAZOLE DERIVATIVE | HDAC3, GABRA5, HDAC2 | SORD 1704/4885ESR1 1775/4885ESR2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.